REDD1、Bcl-2在50例卵巢高级别浆液性癌中的表达及临床意义

The expression and clinical significance of REDD1 and Bcl-2 in 50 cases ovarian high-grade serous carcinoma

目的:在我们前期体外细胞和裸鼠成瘤实验研究结果的基础上,检测新癌基因REDD1和Bcl-2在人卵巢高级别浆液性癌组织中的表达,分析其与临床病理因子之间的关系及二者的相关性。方法:应用免疫组织化学链霉素抗生物素-过氧化物酶复合法(S-P)检测REDD1、Bcl-2在50例卵巢高级别浆液性癌组织中的表达。结果:REDD1在Ⅲ、Ⅳ期高级别浆液性癌组织中的表达明显高于Ⅰ～Ⅱ期(P<0.05),在有腹水病例组中的表达高于无腹水组(P<0.05);Bcl-2在Ⅲ、Ⅳ期高级别浆液性癌组织中的表达明显低于Ⅰ～Ⅱ期(P<0.05),在无腹水的病例组中的表达高于有腹水组(P<0.05);REDD1和Bcl-2在卵巢癌组织中的表达与化疗反应无关(P>0.05)。结论:REDD1、Bcl-2可能参与了卵巢高级别浆液性癌的发生,联合检测二者的表达可能有助于卵巢癌临床预后的评估。

Objective： Based on our previous in vitro and in vivo experiments,investigate the correlation between the expression of new oncogene REDD1,Bcl-2 and clinical-pathologic factors in human ovarian high-grade serous carcinoma.Methods：Immunohistochemical staining of REDD1 and Bcl-2 expression were analyzed in 50 primary ovarian high-grade serous carcinoma using tissue microarray.The correlation between the expression of the REDD1,BCL-2 and clinical factors（stage,ascites and chemotherapy response） were analyzed.Results：The expression of REDD1 was significantly higher in the FIGO stage III、IV than stageⅠ/Ⅱ tissues（P 0.05）,and significantly higher in the patients with ascites group than without it（P0.05） in ovarian high-grade serous carcinoma tissues.Furthermore,the expression of Bcl-2 was significantly lower in the FIGO stage III,IV than stageⅠ/Ⅱ（P0.05）,and significantly lower in the patients with ascites group than without it in ovarian high-grade serous carcinoma tissues（P0.05）.There was no correlation between the expression of REDD1,Bcl-2 and the patients＇ response to chemotherapy in ovarian high-grade serous carcinoma（P 0.05）.Conclusion：Conclusion： REDD1and Bcl-2 may involve in the initiation and progression of human ovarian high-grade serous carcinoma.Detection of expression of REDD1 and Bcl-2 may have prognostic value in ovarian high-grade serous carcinoma.